Lisata Therapeutics Holds Annual Shareholder Meeting

• Lisata Therapeutics shareholders approved a reverse stock split ranging from 1-for-5 to 1-for-15 at the November 9, 2026, annual meeting.
• The equity incentive plan and employee stock purchase plan won approval, with initial reserves of 44,764,472 and 3,730,372 shares, respectively.
• Shareholders authorized adjournment; voting on Series C Non-Voting Convertible Preferred Stock conversion was deferred to November 30, 2026.
• Cynthia L. Flowers and Dr. Ted W. Love were elected directors.
• Stockholders ratified Grant Thornton LLP as independent auditor for the year ending December 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-042818), on November 09, 2026, and is solely responsible for the information contained therein.